Protecting a blockbuster diabetes treatment for AstraZeneca
AstraZeneca AB
Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini
Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million
Intellia Therapeutics, Inc.
Finnegan secures favorable ITC ruling related to innovative electric SUVs for BMW
BMW of North America, LLC and Bayerische Motoren Werke AG
Finnegan fights for Sony’s “exceedingly famous” mark
Sony Group Corporation
Experience
Protecting a blockbuster diabetes treatment for AstraZeneca Protecting a blockbuster diabetes treatment for AstraZeneca
1:18-cv-00664, D. Del., Judge Andrews
Experience
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc. Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc.
18-2097, Fed. Cir., Judges Lourie, O'Malley, Reyna
Experience
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
2:10-cv-06908, E.D. Pa., Judges Angell, Savage, Cohen (Special Master)
13-1544, 16-2647, Fed. Cir., Judges Hughes, Lourie, Moore, Newman, Plager
Experience
District court finds patent covering AstraZeneca’s type II diabetes drugs Onglyza® and Kombiglyze® valid in ANDA litigation District court finds patent covering AstraZeneca’s type II diabetes drugs Onglyza® and Kombiglyze® valid in ANDA litigation
1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
Experience
University of Western Australia v. Academisch Ziekenhuis Leiden University of Western Australia v. Academisch Ziekenhuis Leiden
106,007, 106,008, 106,013, PTAB
Experience
Novartis Vaccines & Diagnostics, Inc. v. MedImmune, LLC Novartis Vaccines & Diagnostics, Inc. v. MedImmune, LLC
1:11-cv-00084, D. Del., Judges Robinson, Thynge
Experience
DuPont prevails on a written description defense to patent infringement at the Federal Circuit DuPont prevails on a written description defense to patent infringement at the Federal Circuit
12-1433, Fed. Cir., Judges Rader, Schall, Bryson
Experience
District court finds patent covering Cephalon’s wakefulness improving drug Nuvigil®, valid in ANDA litigation District court finds patent covering Cephalon’s wakefulness improving drug Nuvigil®, valid in ANDA litigation
1:10-md-02200, D. Del., Judge Sleet
Experience
Federal Circuit reverses district court ruling of invalidity and upholds rulings on other grounds in favor of Finnegan client Eli Lilly and Co. Federal Circuit reverses district court ruling of invalidity and upholds rulings on other grounds in favor of Finnegan client Eli Lilly and Co.
10-1500, -1520, -1521, -1522, -1523, -1524, Fed. Cir., Judges Lourie, Newman
2:07-cv-03770, D.N.J., Judges Cavanaugh, Dickson, Falk
Experience
Eli Lilly & Co. v. Wockhardt Ltd. Eli Lilly & Co. v. Wockhardt Ltd.
1:08-cv-01547, S.D. Ind., Judges Baker, Lawrence, Pratt
Experience
U.S. Court finds patent covering AstraZeneca’s anti-cholesterol drug Crestor®, is valid and enforceable in ANDA litigation U.S. Court finds patent covering AstraZeneca’s anti-cholesterol drug Crestor®, is valid and enforceable in ANDA litigation
1:08-md-01949, D. Del., Judges Farnan, Stark
10-1460, -1461, -1462, -1463, -1464, -1465, -1466, -1467, -1468, -1469, -1470, -1471, -1472, -1473, Fed. Cir., Judges Mayer, Newman, Plager
Experience
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc. Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
1:06-cv-00238, S.D. Ind., Judges Barker, McVicker Lynch, Magnus-Stinson
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.